Weave Bio Therapeutics
Silk. For Hollow Organ Regeneration. Platform technology that enables hollow organ regeneration using bioresorbable, non-immunogenic silk scaffolds. Preclinical validation in urethral strictures, hypospadius, bladder augmentation, ureteral strictures and ileal conduits.
Weave Bio Therapeutics
Weave Bio Therapeutics is currently seeking investment
Weave Bio Therapeutics is seeking a series-a investment in the range of 5m-20m
Key People
Vikas Agarwal
CEO